Abstract | PURPOSE: EXPERIMENTAL DESIGN: RESULTS: High ERCC1 expression was associated with short survival (237 days vs. 453 days, log-rank P = 0.03), but not with response to chemotherapy or PFS. And high BCRP expression was associated with short survival (214 days vs. 412 days, log-rank P = 0.02) but not with response to chemotherapy or PFS. Multivariate analysis confirmed that negativity for the expression of BCRP tends to be an independent variable related to overall survival (P = 0.06). CONCLUSIONS: This study examined ERCC1 and BCRP expression in biopsy specimens as candidates for predictors of the survival of patients with advanced NSCLC treated with platinum-based chemotherapy.
|
Authors | Shuji Ota, Genichiro Ishii, Koichi Goto, Kaoru Kubota, Young Hak Kim, Masakazu Kojika, Yukinori Murata, Manabu Yamazaki, Yutaka Nishiwaki, Kenji Eguchi, Atsushi Ochiai |
Journal | Lung cancer (Amsterdam, Netherlands)
(Lung Cancer)
Vol. 64
Issue 1
Pg. 98-104
(Apr 2009)
ISSN: 0169-5002 [Print] Ireland |
PMID | 18823676
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- ABCG2 protein, human
- ATP Binding Cassette Transporter, Subfamily G, Member 2
- ATP-Binding Cassette Transporters
- Antineoplastic Agents
- Biomarkers, Tumor
- DNA-Binding Proteins
- Neoplasm Proteins
- ERCC1 protein, human
- Endonucleases
- Cisplatin
|
Topics |
- ATP Binding Cassette Transporter, Subfamily G, Member 2
- ATP-Binding Cassette Transporters
(metabolism)
- Adenocarcinoma
(drug therapy, metabolism, mortality)
- Aged
- Antineoplastic Agents
(therapeutic use)
- Biomarkers, Tumor
(metabolism)
- Biopsy
- Carcinoma, Non-Small-Cell Lung
(drug therapy, metabolism, mortality)
- Cisplatin
(therapeutic use)
- DNA-Binding Proteins
(metabolism)
- Endonucleases
(metabolism)
- Female
- Humans
- Lung Neoplasms
(drug therapy, metabolism, mortality)
- Male
- Neoplasm Proteins
(metabolism)
- Neoplasm Staging
- Prognosis
- Survival Rate
- Treatment Outcome
|